Japan · Hospital & health care startup

REHASAKU

REHASAKU 株式会社リハサク is a Japanese healthcare technology company specializing in rehabilitation and exercise-therapy support.

Funding reportedLast round: Seed

Hospital & health careTokyo, Japan

About REHASAKU

REHASAKU 株式会社リハサク is a Japanese healthcare technology company specializing in rehabilitation and exercise-therapy support.

It operates two main business lines: services for medical institutions and treatment clinics, including osteopathic and chiropractic practices. The company offers a range of solutions, including REHASAKU Medical, an exercise-therapy cloud system for medical institutions, and REHASAKU Cloud, which features an exercise instruction support tool, AI posture analysis, web customer-acquisition consulting, and a reservation management system. For treatment clinics, REHASAKU provides a therapist support platform that facilitates exercise guidance and self-care, enhancing patient satisfaction and revisit rates. Additionally, REHASAKU Posture is an AI service that analyzes posture through images, while REHASAKU reserve is a cloud reservation system tailored for clinics. REHASAKU's mission is to integrate rehabilitation into daily life and improve public health through digital support for physical therapy and rehabilitation workflows. Its services cater to medical institutions and treatment clinics, with notable customers including だいまる鍼灸整骨院 and 株式会社ONE-TO-ONE.

What company datasets say REHASAKU raised

Funding, as reported

Reported in all275Min the source's currency
Rounds3
Last roundSeed
Last round size1.1M
Last round dateAug 2023
Investors listed5

The company, in detail

What they build

Known for

hospital & health carehospitals & health care

Built with from their website

Amazon AWSGoogle Search Console

Sector
Hospital & health care
Region
Tokyo
Full record
Every detail in the company directory

Hospital & health care in Japan

Startups like it

Is this your company?

Add your raise, your deck and your story, and put REHASAKU in front of investors. Or tell us what we have wrong.